CC-486 is in development for relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). AITL is a fast-growing type of T-cell Non-Hodgkin Lymphoma marked by enlarged lymph nodes and increased antibodies in the blood. Other symptoms may include a skin rash, fever, weight loss, or night sweats. AITL is more resistant to conventional chemotherapy than other forms of lymphoma and is generally associated with a poor outcome. In relapsed or refractory disease, survival durations are in the range of only a few months meaning there is unmet medical need in this patient population.
CC-486 is an oral drug that can be incorporated into the genetic material of cells (RNA and DNA) instead of their natural building-block, cytidine. It is thought to work by altering the way the cell turns genes on and off and also by interfering with the production of new RNA and DNA. This helps to correct the problems with the maturation and growth of young blood cells in the bone marrow and to kill cancerous cells in blood cancers. If licenced, CC-486 will provide an additional therapy option for AITL patients who have relapsed or become resistant to previous treatment.
Pembrolizumab in addition to chemotherapy, followed by maintenance with olaparib is in clinical development for the first line treatment of Breast Cancer Gene (BRCA) non-mutated advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Ovarian cancer includes a group of tumours that arise from diverse types of tissue contained in the ovary and can often spread from the ovary to any surface within the abdominal cavity including the fallopian tubes and peritoneal cavity. While current treatments exist for these advanced cancers of the female reproductive system, significant unmet medical need remains for more effective treatment options with manageable safety profiles for patients in the first line setting.